The Principal Investigator Sample Clauses

The Principal Investigator shall be supported in the execution of the Clinical investigation by the healthcare and non-healthcare personnel and by any contractors engaged by the Entity, as appointed by the Entity and operating under its responsibility for all aspects pertaining to this Clinical investigation, who are qualified to conduct the Clinical investigation, and who have previously received adequate training as provided for in the applicable laws, by the Sponsor/CRO and who have declared their willingness to take part in the Clinical investigation (the Co-investigators). Without affecting the foregoing, the definition of “Investigators” does not include any medical or non-medical personnel who perform proprietary institutional activities in the context of the Clinical investigation (for example pharmacists, IT technicians).

The Principal Investigator shall keep all of the Case Report Forms (CRF), duly compiled, in accordance with the terms and conditions of the Protocol for the Clinical investigation and with the applicable regulations, in printed or digital form, and in any case they shall be delivered promptly in accordance with the GCP, by the date indicated in the Clinical investigation Protocol.

The Principal Investigator. 5.1. Xxxxx X. Xxxxx MD, PhD of the Medical Center (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Fund shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Fund not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability. 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Fund and/or any third party acting on their behalf in direct or indirect connection with such replacement.

The Principal Investigator for the Contract or Grant shall be responsible for executing the project in conformance with the approved budget.

The Principal Investigator. For sake of clarity, the Principal Investigator is an employee of Institution and will be named in Exhibit A. The Principal Investigator represents and certifies that he or she has read and understands the Investigator’s Brochure. The Principal Investigator is not a party but must sign off read and acknowledged to the entire agreement. Prior to the commencement of the Study, the Principal Investigator shall deliver to AstraZeneca true, complete and correct copies of the Principal Investigator’s investigator statement on U.S. Food and Drug Administration (“FDA”) Form 1572 and curriculum vitae, each of which shall be signed by the Principal Investigator. During the Study, the Institution shall immediately notify AstraZeneca in writing at such time as it becomes aware that the Principal Investigator plans to leave the Institution or shall be unable to complete the Study. If the Institution and AstraZeneca are unable to agree on an acceptable substitute investigator within fifteen (15) business days following such notice, AstraZeneca may terminate this Agreement pursuant to Section 24.

The Principal Investigator. Project Promoter and Project Partner(s) undertake to post in all scientific publications, which are related to Project outcomes: The research leading to these results has received funding from the Norwegian Financial Mechanism 2014-202124 and correct Project registration number.

The Principal Investigator. Xxxxxx Xxx Xxxx – will coordinate the entire project and will have full responsibility of the project development.

The Principal Investigator. Xx. Xxxxx Xxxx;

The Principal Investigator. CV Higher education Work experience and research positions

The Principal Investigator and the Institution must use the wording below when acknowledging a grant from XXXXX. When appropriate, such as in a scientific journal article, the grant number must be included.